{"nctId":"NCT02962648","briefTitle":"An Extension Trial to Assess the Safety of Re-dosing of Iron Isomaltoside/Ferric Derisomaltose (Monofer®/Monoferric®)","startDateStruct":{"date":"2017-01-09","type":"ACTUAL"},"conditions":["Iron Deficiency Anemia","Iron Deficiency Anaemia"],"count":103,"armGroups":[{"label":"Iron isomaltoside/ferric derisomaltose","type":"EXPERIMENTAL","interventionNames":["Drug: Iron isomaltoside/ferric derisomaltose"]}],"interventions":[{"name":"Iron isomaltoside/ferric derisomaltose","otherNames":["Monofer®, Monoferric®, Monover®, Monofar®, Monoferro®"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Completed one of the lead-in trials\n2. Randomised and dosed with iron isomaltoside/ferric derisomaltose in one of the lead-in trials.\n3. Haemoglobin (Hb) of ≤ 11 g/dL\n4. Screening serum ferritin (s-ferritin) ≤ 100 ng/mL, or ≤ 300 ng/mL if transferrin saturation (TSAT) ≤ 30 %\n5. Willingness to participate and signing the informed consent form (ICF)\n\nExclusion Criteria:\n\n1. Intravenous (IV) iron treatment between the lead-in trial and screening\n2. During 30-day period prior to screening or during the trial period; has or will be treated with a red blood cell transfusion, radiotherapy, and/or chemotherapy\n3. Received an investigational drug within 30 days of screening\n4. Decompensated liver cirrhosis or active hepatitis\n5. Pregnant or nursing women.\n6. Any other laboratory abnormality, medical condition, or psychiatric disorders which, in the opinion of the Investigator, will put the subject's disease management at risk or may result in the subject being unable to comply with the trial requirements","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Subjects With Adverse Drug Reactions (ADR)","description":"Safety\n\nEvaluate the number of subjects with adverse drug reactions (ADRs), defined as AEs that were assessed by the investigator as related or possible related to the investigational product.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of Protocol-defined Serious or Severe Hypersensitivity Reactions","description":"Safety.\n\nFor this endpoint, the number of participants with serious or severe hypersensitivity reactions were evaluated. The hypersensitivity terms that were included in the analysis were those that started or after the first dose of treatment (i.e. treatment emergent). The terms used to define hypersensitivity were those specified by the Standardised MedDRA Queries (SMQ) for hypersensitivity, plus four additional terms: Loss of consciousness; Seizure; Syncope; Unresponsiveness.\n\nThe potential hypersensitivity AEs were adjudicated in a blinded fashion by an independent Clinical Endpoint Adjudication Committee (CEAC).\n\nResults show only those participants that had adjudicated and confirmed serious or severe hypersensitivity reactions.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Composite Cardiovascular Adverse Events (AEs)","description":"Safety\n\nResults show the composite cardiovascular AEs, that started on or after the first dose of treatment (i.e. treatment emergent) up to month 6.\n\nThe reported potential cardiovascular AEs were adjudicated in a blinded fashion by an independent Clinical Endpoint Adjudication Committee (CEAC).\n\nThe potential cardiovascular AEs included the following:\n\n* Death due to any cause\n* Non-fatal myocardial infarction\n* Non-fatal stroke\n* Unstable angina requiring hospitalisation\n* Congestive heart failure requiring hospitalisation or medical intervention\n* Arrhythmias\n* Hypertension\n* Hypotension\n\nResults show only those participants that had adjudicated and confirmed treatment-emergent composite cardiovascular AEs.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to First Composite Cardiovascular Safety AE","description":"Safety\n\nTime to first composite cardiovascular AE was defined as the actual time in days from first dose of treatment until the date of the composite cardiovascular AE. For subjects not reporting a composite cardiovascular AE, the time was censored at the date of the last attended visit. Only the adjudicated and confirmed composite cardiovascular safety AEs, as judged by the Clinical Endpoint Adjudication Committee (CEAC), were considered for this endpoint.\n\nTime to first composite cardiovascular AE was defined as the actual time in days from first dose of treatment until the date of the composite cardiovascular AE. For subjects not reporting a composite cardiovascular AE, the time was censored at the date of the last attended visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"S-phosphate <2 mg/dL at Any Time From Baseline to Week 26","description":"Safety\n\nResults show the number of trial participants and their status of s-phosphate \\<2 mg/dL, at any time from baseline to week 26.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null}]},{"measurements":[{"groupId":"OG000","value":"94","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Hb From Baseline to Week 2, 13, and 26","description":"Efficacy.\n\nChange in Hb from baseline to week 2, 13, and 26.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.23","spread":"1.40"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.73","spread":"1.83"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.34","spread":"1.93"}]}]}]},{"type":"SECONDARY","title":"Change in S-ferritin From Baseline to Week 2, 13, and 26","description":"Efficacy.\n\nChange in s-ferritin from baseline to week 2, 13, and 26.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"255.6","spread":"177.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"87.9","spread":"123.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"93.9","spread":"180.4"}]}]}]},{"type":"SECONDARY","title":"Change in Transferrin Saturation (TSAT) From Baseline to Week 2, 13, and 26","description":"Efficacy\n\nChange in transferrin saturation (TSAT) from baseline to week 2, 13, and 26.\n\nTSAT is the value of serum iron divided by the total iron-binding capacity and the unit is %, which referrers to % of iron-binding sites of transferrin being occupied by iron.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.16","spread":"11.87"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.42","spread":"10.81"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.78","spread":"10.63"}]}]}]},{"type":"SECONDARY","title":"Change in S-iron From Baseline to Week 2, 13, and 26","description":"Efficacy.\n\nChange in s-iron from baseline to week 2, 13, and 26.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21.1","spread":"50.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.7","spread":"45.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.0","spread":"44.1"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":13,"n":102},"commonTop":["Fatigue","Abdominal pain","Urinary tract infection","Dizziness","Headache"]}}}